Repligen | RGEN - Operating Expenses


Repligen reported $177.94M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
Agilent USD 1.44B 27M Dec/2025
Align Technology USD 822.85M 11.8M Dec/2025
Bio Techne USD 241.42M 2.52M Dec/2025
BioMarin Pharmaceutical USD 676.18M 131.65M Dec/2025
Bristol-Myers Squibb USD 8.3B 10.25B Dec/2025
Bruker USD 900.9M 124.3M Dec/2025
Charles River Laboratories USD 918.41M 2.49B Dec/2025
Danaher USD 5.34B 45.74B Dec/2025
Dentsply International USD 423M 1.06B Dec/2025
Exact Sciences USD 875.74M 62.51M Sep/2025
General Electric Aerospace USD 10.94B 7.87B Dec/2025
Henry Schein USD 3.25B 110M Dec/2025
Illumina USD 903M 69M Dec/2025
IQVIA Holdings USD 1.69B 4.47B Dec/2025
Mettler Toledo International USD 777.8M 42.3M Dec/2025
Myriad Genetics USD 229M 3.4M Sep/2025
OraSure Technologies USD 23.07M 4.36M Sep/2024
Pacific Biosciences Of California USD 74.08M 107.7M Sep/2024
Pfizer USD 12.91B 79.89B Dec/2025
Repligen USD 177.94M 1.82M Dec/2025
Revvity USD 626.22M 25.62M Dec/2025
Standard Biotools USD 43.02M 2.44M Sep/2025
Thermo Fisher Scientific USD 9.91B 867M Dec/2025
Waters USD 661.85M 1.67B Dec/2025
West Pharmaceutical Services USD 642.5M 2.41B Dec/2025